News from mgb biopharma

A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.

Latest

27 Jan, 2021, 08:00 GMT MGB Biopharma - Successful End-of-Phase 2 Meeting with FDA for MGB-BP-3, a Potential New Gold Standard, First-Line Treatment for Clostridioides difficile Infection (CDI)

MGB Biopharma, a biopharmaceutical company developing MGB-BP-3, a novel antibacterial, for the treatment of Clostridioides difficile (CDI), today...

10 Oct, 2019, 09:30 GMT MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance,...

30 Aug, 2019, 08:00 GMT MGB Biopharma Announces Completion of Funding Round

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance,...

24 Jan, 2019, 09:00 GMT MGB Biopharma - FDA and Health Canada Clear IND/CTA Applications for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)

Phase IIa trial to evaluate MGB-BP-3 in patients with CDAD on track to start in Q1 2019 MGB Biopharma, a biopharmaceutical company developing a novel ...

06 Apr, 2017, 08:00 GMT MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance,...

12 Sep, 2016, 08:00 GMT MGB Biopharma Granted Qualified Infectious Disease Product (QIPD) Designation by U.S. FDA for the Treatment of Clostridium Difficile-associated Diarrhoea (CDAD) for MGB-BP-3

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance,...

14 Jun, 2016, 08:00 GMT MGB Biopharma to Present Poster at Upcoming ASM Microbe Meeting in Boston on 20 June 2016

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem of antibiotic...

19 May, 2016, 10:11 GMT MGB Biopharma Welcomes Jim O'Neill's Final Recommendations for the World to Defeat Superbugs

MGB Biopharma, a Biopharmaceutical Company Developing a Truly Novel Class of Anti-infectives, Welcomes the Final Instalment of Lord Jim O'Neill's...

09 May, 2016, 07:00 GMT MGB Biopharma's Pre-IND Meeting With FDA Provides Clear Guidelines on Further Development of Oral MGB-BP-3, a Truly Novel Antibiotic Targeting Clostridium Difficile Infections

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem of antibiotic...

15 Feb, 2016, 09:00 GMT MGB Biopharma and University of Strathclyde Sign New Agreement to Develop Novel MGB Anti-Infectives to Tackle a Key Mechanism of AMR

New compounds designed to overcome efflux pump mediated bacterial resistance MGB Biopharma, a biopharmaceutical company developing a truly novel...

21 Jul, 2015, 08:00 GMT MGB Biopharma Commences Phase I Clinical Trial With Oral Formulation of MGB-BP-3 for the Treatment of Multi-Resistant Clostridium Difficile Infections

- MGB Biopharma is at the forefront of efforts to tackle the global rise in antibiotic resistant infections MGB Biopharma, a biopharmaceutical...

02 Jun, 2015, 08:00 GMT MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections

MGB Biopharma at the forefront of addressing the global antibiotic resistance problem MGB Biopharma, a biopharmaceutical company developing a truly...

12 Jan, 2015, 09:00 GMT MGB Biopharma Continues to Progress its Truly Novel Anti-infectives Platform to Tackle Antibiotic Resistance in 2014

Highlights In September 2014, MGB Biopharma secured £4M ($6.4M) from leading Scottish investors and Innovate UK for further clinical development of...

17 Sep, 2014, 08:00 GMT MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development

First antibacterial with a new mode of action from a truly novel class of anti-infective in over a decade MGB Biopharma, a biopharmaceutical company...

09 Jun, 2014, 11:30 GMT MGB Biopharma Receives £1.3m Grant Award from the UK's Technology Strategy Board's Biomedical Catalyst

Grant to help fund Phase I trial with lead candidate oral MGB-BP-3 for Clostridium difficile MGB Biopharma, a biopharmaceutical company developing...

02 Jun, 2014, 08:00 GMT MGB Biopharma Expands Scientific Advisory Board (SAB) with Medical Microbiologist Dr Stephanie Dancer

MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that Dr Stephanie Dancer, an internationally...

18 Nov, 2013, 09:00 GMT MGB Biopharma Adds its Support to European Antibiotic Awareness Day

MGB Biopharma, one of Europe's leading biopharmaceutical companies developing truly novel anti-infectives, announces its support for the European...

04 Nov, 2013, 09:11 GMT MGB Biopharma to Present at Bio-Europe 2013

MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that CEO Dr Miroslav Ravic will present at...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.